

VIRGINIA SOCIETY OF HEALTH-SYSTEM PHARMACISTS



PRESENTS

THE 2007 FALL SEMINAR

***EMBASSY SUITES HOTEL
AT HAMPTON ROADS CONVENTION CENTER***

OCTOBER 5-6

***14.0 HOURS OF CONTINUING EDUCATION FOR
PHARMACISTS AND TECHNICIANS
TECHNICIAN WORKSHOP***

Thursday, October 4

- 12:00-1:00 pm Political Action Committee
Board of Trustees Meeting
- 1:00-5:00pm VSHP Board of Directors Meeting
(Open to All Members)
- 5:30-6:00 pm Cocktail Reception
- 6:00 pm Past Presidents' Banquet

Friday, October 5

- 7:00-8:30 am Registration/Breakfast
Stroke Overview:
Stroke Knowledge is Power
Sponsored by sanofi-aventis U.S.
- 8:30-10:00 am Gynecologic Malignancies –
A Treatment Overview

- ACPE #108-000-07-029-L01 (.15 CEU)
- 10:00-11:00 am Ovarian Cancer: A Patient's Perspective
ACPE #108-000-07-030-L01 (.10 CEU)
- 11:00 -11:15am Break
- 11:15-12:15 am Update on Treatment of Bipolar Disorder
ACPE #108-000-07-027-L01 (.10 CEU)
- 12:15-1:45 pm Lunch/Exhibit Program
including Poster Session
- 1:45-2:45 pm Treatment of Acute Agitation
ACPE #108-000-07-031-L01 (.10 CEU)
- 2:45-3:45 pm Emerging Safety Issues with
Erythropoiesis-Stimulating Agents
ACPE #108-000-07-032-L01 (.10 CEU)
- 3:45-4:00 pm Break
- 4:00-5:00 pm An Evaluation of New Treatment Options
for Type II Diabetes
ACPE #108-000-07-033-L01 (.10 CEU)
- 5:00-7:00 pm Exhibit Program including Poster Session
- 7:00-7:45 pm Update on Antifungals (.10 CEU)
Sponsored by Astellas
- 7:45 – 9:45 pm Awards Banquet

Saturday October 6

- 7:00-8:30 am Breakfast with Antibiotic Presentation
Sponsored by Ortho-McNeil
- 8:30-9:30 am Protecting Our Patients with Sleep Apnea
ACPE #108-000-07-034-L01 (.10 CEU)
- 9:30-10:30 am Management of Obesity
ACPE #108-000-06-004-L01 (.10 CEU)
- 10:30-10:45 am Break
- 10:45-12:15 am Technology Updates
ACPE #108-000-07-035-L04 (.15 CEU)
- 12:15-1:45 pm ASHP Lunch Symposium on
Acute Coronary Syndrome (.10 CEU)
- 1:45 – 2:45 pm Don't Get Caught Breathless:
An Update in Asthma Management
ACPE #108-000-07-036-L01 (.10 CEU)
- 2:45 – 3:45 pm Update on Chronic
Obstructive Pulmonary Disease (COPD)
ACPE #108-000-07-037-L01 (.10 CEU)

VIRGINIA SOCIETY OF HEALTH-SYSTEM PHARMACISTS

The **Virginia Society of Health-System Pharmacists** invites you to the premier continuing education seminar of the year. The VSHP 2007 Fall Seminar will be held October 5-6 at the Embassy Suites Hotel at Hampton Roads Convention Center.

We have developed an outstanding program including:

- 14 hours of the highest quality continuing education on topics you have requested.
- A VSHP Political Action Committee **Silent Action** offering fabulous trips, prizes and items that your don't want to miss.
- 4 hour Exhibit Program featuring the latest pharmaceutical developments, products, equipment and services available.
- Poster presentation session showcasing recent research and projects submitted by VSHP members.
- Our Annual Awards Program sponsored by Astellas honoring this year's recipients of the Pharmacist of the Year, Clinical Pharmacy Practice Achievement, Technician of the Year, New Practitioner of the Year and Student Awards (visit at our website at www.vshp.org to submit nominations).

Hotel Information

VSHP has negotiated room rates at the Embassy Suites Hotel at Hampton Roads Convention Center. Reservations should be made directly by the individual with Embassy Suites reservations at 1-800-EMBASSY, 757-827-8200 or online at www.embassysuites.com no later than September 4. After this date, reservations will be accepted by the hotel on a space-available basis and at the hotel's prevailing rate.

Single/Double \$139.00

Embassy Suites Hotel at
Hampton Roads Convention Center
1700 Coliseum Drive
Hampton, VA 23666

Cancellation/Grievance Policy

To receive a refund, confirmed registrations must be canceled in writing on or before September 23, 2007 (postmark or fax date); cancellations postmarked on or before September 23 will be subject to a \$25.00 handling charge. Refunds will be issued only for cancellations faxed or postmarked before September 23.

Should any registrant be dissatisfied with the quality of the continuing education program, the participant may submit their grievance in writing to the attention of the Continuing Education Administrator (CEA), VSHP, P.O. Box 2567, Fairfax, VA 22031-2567 within 5 days of the conclusion of the program. The CEA will review the grievance within 10 days of receipt and provide written response of the findings and the basis for the decision made to the complainant no later than 30 days after receipt of the written grievance.



The Virginia Society of Health-System Pharmacists is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmaceutical education. Registrants may obtain up to 14.0 contact hours (1.40 CEUs) at the VSHP 2007 Fall Seminar. Attendees must attend the entire time allotted for each session, complete a Speaker and Program Evaluation Form on-site for each session attended, and present it at the registration desk at the conclusion of the program for validation. VSHP will provide validated Statements of Continuing Pharmaceutical Education to meeting participants no

later than 30 days after the completion of the program. This program is directed toward all individuals actively engaged in the practice of pharmacy.

ASHP ADVANTAGE LUNCH SYMPOSIUM

EVIDENCE-BASED STRATEGIES FOR IMPROVING PATIENT OUTCOMES: FOCUS ON ANTITHROMBOTIC THERAPY IN THE MANAGEMENT OF ACUTE CORONARY SYNDROME

Faculty

Sarah A. Spinler, Pharm.D., FCCP, BCPS
Professor of Clinical Pharmacy
University of the Sciences in Philadelphia
Philadelphia, Pennsylvania

Learning Objectives

- Describe the clinical and economic burden and pathophysiology of acute coronary syndrome (ACS).
- State pharmacologic treatment strategies and expected outcomes for patients with acute coronary syndrome as recommended by the American College of Cardiology/American Heart Association guidelines for the management of patients with non-ST-segment elevation (NSTEMI) ACS and ST-segment elevation myocardial infarction (STEMI).
- Summarize the latest clinical research, and its potential impact on therapy, regarding antithrombotic therapy in the management of patients with NSTEMI ACS and STEMI, including a comparison of the safety and efficacy of unfractionated heparin, low-molecular-weight heparin, fondaparinux, and bivalirudin.
- Describe the role of evidence-based clinical guidelines and performance measurement in improving the quality of patient care and the potential role of pharmacists in their implementation.

This presentation is planned by ASHP Advantage and supported by an educational grant from sanofi-aventis U.S.

A web-based educational program has been designed to enhance your baseline knowledge of ACS prior to the live program. Visit <http://symposia.ashp.org/acs-essentials/>



Continuing Education Accreditation

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of pharmacy education. The program provides 1.0 hour (0.1 CEU) of continuing education credit (Program Number 204-000-07-414-L01). Attendees must complete a Continuing Pharmacy Education Request online and may immediately print their official ASHP CE statements at the ASHP Advantage CE Processing Center at www.ashpadvantage.com. For complete program information, visit www.ashpadvantage.com/clot.

Call for Nominations

The Selection Committee is seeking nominations from our membership for the VSHP Pharmacist of the Year, Clinical Practice Achievement, New Practitioner of the Year and the Technician of the Year Awards. Please consider nominating a colleague(s) for these awards. Submit your nominations with a brief summary of the nominee's contributions using the following criteria:

VSHP Pharmacist of the Year

- Service to the profession of pharmacy, specifically health system pharmacy
- Contributions to pharmacy programs within the Commonwealth
- Cooperation and contributions to the health-care team
- Recognized by the profession as a leader within pharmacy
- Service to the community

Clinical Pharmacy Practice Achievement Award

- Presented to one or more VSHP members who have made a recent contribution (within the last two years) to the development and provision of a patient-oriented pharmacy service
- The contribution shall involve direct patient care and/or public visibility in some capacity
- The contribution shall have a measurable or predictable effect on patient care outcomes
- Contributions can represent the innovative efforts of an individual or a group of individuals (several individuals or department)

VSHP New Practitioner of the Year

- Earned his/her first pharmacy degree within the previous 5 years
- Supports VSHP by membership, meeting attendance, and participation
- Promotes the pharmacy profession within the Commonwealth
- Provides service to community
- Demonstrates superior leadership, innovation, clinical skill or other talent compared to other new practitioners

VSHP Technician of the Year

- Service to the profession as a Pharmacy Technician
- Must be a Certified Pharmacy Technician
- Contributions to pharmacy programs within the Commonwealth
- Cooperation and contributions to the health-care team
- Recognized by the profession as a leader within pharmacy
- Service to the community

Please submit your nomination(s) by September 1 by fax at (703) 323-5233 or by email at VSHP@aol.com, Attention: Selection Committee. Don't miss this opportunity to recognize a colleague or friend for their service and commitment to the profession of pharmacy.

Continuing Education Learning Objectives:

STROKE OVERVIEW: STROKE KNOWLEDGE IS POWER

Gregg S. Morrow, Pharm.D.
Cardiovascular - Regional Medical Liaison
sanofi-aventis U.S.

- Define the epidemiology of stroke.
- Describe the pathophysiology of stroke.
- List and describe stroke risk factors.
- Summarize the significant cross risk associated with atherothrombosis.
- Describe stroke guidelines.
- Describe the "gaps" in stroke management.

GYNECOLOGIC MALIGNANCIES – A TREATMENT OVERVIEW

Douglas L. Smith, Pharm.D., BCNSP, BCOP
Associate Professor, Department of Pharmacy
Bernard J. Dunn School of Pharmacy
Shenandoah University

- State the current American Cancer Society (ACS) recommendations for screening and early detection for ovarian, cervical and endometrial cancers.
- Define the role of intraperitoneal (IP) chemotherapy in the treatment of ovarian cancer.
- State the advantages and disadvantages of IP chemotherapy in the treatment of ovarian cancer.
- State common risk factors associated with the development of endometrial cancer.
- Define the role of chemotherapy in treating endometrial cancer.
- State common risk factors associated with the development of cervical cancer.
- Define the role of chemotherapy in treating cervical cancer.
- Outline the indications for Human Papilloma Virus (HPV) vaccination.

OVARIAN CANCER: A PATIENT'S PERSPECTIVE

Treacy A. Mallon, Pharm.D.
Bioniche Development Inc.

- List and describe the signs and symptoms associated with ovarian cancer.
- Describe new pharmacologic treatments for ovarian cancer.
- List side effects resulting from ovarian cancer and treatment options.
- Describe strategies for the management of side effects.
- Summarize the difficulties experienced by cancer patients and their families.
- Describe ways that family, community and healthcare providers can assist cancer patients with their battle.

UPDATE ON THE TREATMENT OF BIPOLAR DISORDER

Thomas C. Snader, Pharm.D., CGP, FASCP
President, TCS Pharmacy Consultants
Clinical Professor of Clinical Pharmacy

University of the Sciences in Philadelphia

- Compare and contrast differences between the various classifications of Bipolar Disorder and their relevance to treatment planning.
- Describe the current consensus approach to designing therapy for various stages and classification of Bipolar Disorder.
- Summarize various clinical trials concerning the use of atypical antipsychotics and mood stabilizers alone and in combination.
- Describe the newest dosage consideration for the use of divalproex sodium in the treatment of Bipolar Disorder including side effects and clinical consideration to use in drug selection.

MANAGEMENT OF ACUTE AGITATION

Gregory A. Chenault, Pharm.D.

Clinical Specialist Critical Care

Virginia Commonwealth University Health System

- Describe methods for a pharmacist to assess and prioritize etiologies for acute agitation in the hospitalized patient.
- Define the pathophysiology of acute agitation.
- List and describe methods to document the severity of acute agitation.
- Compare the benefits and risks of current therapies for acute agitation.
- Summarize the pharmacist's role in a multidisciplinary approach to the management of acute agitation.

EMERGING SAFETY ISSUES WITH ERYTHROPOIESIS-STIMULATING AGENTS

Nicole Leyland Metzger, Pharm.D.

Adult Internal Medicine Specialty Resident

Virginia Commonwealth University Health System

- Describe erythropoiesis and the pathophysiology of anemia.
- Compare and contrast the pharmacology of erythropoiesis- stimulating agents (ESAs).
- Summarize the standard of care for the use of ESAs in chronic kidney disease, oncology, and critically ill patients.
- Evaluate recent literature regarding the safety and efficacy of ESAs and provide therapeutic recommendations.
- Describe ESA reimbursement changes that have been proposed by The Centers for Medicare and Medicaid Services.

AN EVALUATION OF NEW TREATMENT OPTIONS FOR TYPE II DIABETES

Martin Treye Heim, Pharm.D., BCPS

Assistant Professor of Pharmacy Practice

University of Appalachia College of Pharmacy

- Identify new treatment options for Type II Diabetes.
- Classify and compare new therapeutic agents by mechanism of action.
- Recommend patients who might benefit from new therapeutic agents.
- Describe monitoring parameters for patients receiving new therapeutic agents.
- Compare and contrast new therapeutic agents to traditional agents with respect to clinical efficacy.

UPDATE ON ANTIFUNGALS

Elizabeth S. Dodds

Associate Professor

Duke University

- Describe the changing epidemiology of invasive fungal infections.
- Outline the role of newer antifungal agents.
- Describe unique aspects of the pharmacology of antifungal agents and the role of the pharmacist in safely administering these therapies.

PROTECTING OUR PATIENTS WITH SLEEP APNEA

Rachelle Collins, Pharm.D.

Coordinator, Clinical Pharmacy Services

Chesapeake General Hospital

- Describe the pathophysiology of sleep apnea.
- Describe how to screen patients who may have sleep apnea.
- Describe the risk of narcotic use in patients with sleep apnea.
- Describe why traditional monitoring of PCA patients may not be the most effective method.
- Summarize the importance of capnography in protecting sleep apnea patients.

MANAGEMENT OF OBESITY

Renee Ahrens Thomas, Pharm.D., MBA

Associate Professor, Pharmacy Practice Department

Shenandoah University, Bernard J. Dunn School of Pharmacy

- Identify the health, social, and economic consequences of obesity.
- Describe the goals of weight management and treatment.
- Describe the different strategies for weight loss and maintenance.
- Identify general recommendations for diet and exercise in weight management.
- Compare and contrast the different pharmacologic agents used for weight loss.

TECHNOLOGY UPDATE

Rodney L. Stiltner, Pharm.D.

Director of Pharmacy

Virginia Commonwealth University Health System

Ian Orensky, Pharm.D., MS

Pharmacy Supervisor

Virginia Commonwealth University Health System

Perry Taylor, Pharm.D.

Informatics Pharmacist

Virginia Commonwealth University Health System

- Describe the roadmap to the electronic medical record for Virginia Commonwealth University Health System.
- Describe different technology applications and the impact to pharmacy and patient safety.
- Define how CPOE impacts pharmacy practice and workflow.
- Summarize the role of the informatics pharmacist.

DON'T GET CAUGHT BREATHLESS:

AN UPDATE IN ASTHMA MANAGEMENT

Punam Patel, Pharm.D., BCPS

Clinical Specialist, Drug Information

Virginia Commonwealth University Health System

Assistant Clinical Professor

Virginia Commonwealth University School of Pharmacy

- Define the epidemiology and pathophysiology of asthma.
- Describe current treatment guidelines and goals of therapy for management of asthma in ambulatory patients.
- Evaluate and summarize recent literature regarding safety and efficacy of select asthma treatments.
- Describe future therapies for asthma control.

UPDATE ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Kristin Miller, MD

Fellow, Pulmonary/Critical Care Medicine

Virginia Commonwealth University Health System

- Define the proposed etiology and pathogenesis of Chronic Obstructive Pulmonary Disease (COPD).
- Recognize the diagnostic criteria for COPD.
- Distinguish COPD from other obstructive lung diseases.
- Summarize the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) criteria to guide pharmacologic management.
- Describe treatment of acute COPD exacerbations.
- Describe non-pharmacologic treatments for COPD.
- Summarize the importance of smoking cessation in patients with COPD.